|
Nov 24, 2021
|
GBT Announces Participation at the 4th Annual Evercore ISI HealthCONx Conference
|
|
|
Nov 12, 2021
|
GBT Announces Participation in Upcoming Investor Conferences
|
|
|
Nov 08, 2021
|
GBT Announces New Employment Inducement Grants
|
|
|
Nov 04, 2021
|
GBT Reports Third Quarter 2021 Financial Results
|
|
|
Nov 04, 2021
|
GBT Announces Six Data Presentations on Sickle Cell Disease at Upcoming 63rd American Society of Hematology (ASH) Annual Meeting & Exposition
|
|
|
Nov 01, 2021
|
GBT Wins Prestigious Prix Galien USA Award for Oxbryta® (voxelotor)
|
|
|
Oct 29, 2021
|
GBT Mourns the Loss of Sickle Cell Warrior Hertz Nazaire
|
|
|
Oct 28, 2021
|
GBT to Announce Third Quarter 2021 Financial Results on Thursday, November 4
|
|
|
Oct 07, 2021
|
GBT Announces New Employment Inducement Grants
|
|
|
Sep 20, 2021
|
GBT Announces Participation at the Cantor Global Healthcare Conference
|
|
|
Sep 14, 2021
|
GBT Establishes The GBT Foundation to Improve the Health and Well-being of Underserved Patient Communities Around the World
|
|
|
Sep 09, 2021
|
GBT Announces New Employment Inducement Grants
|
|
|
Sep 08, 2021
|
GBT and Sickle Cell Disease Association of America to Host 10th Annual Sickle Cell Disease (SCD) Therapeutics Conference
|
|
|
Sep 07, 2021
|
U.S. FDA Accepts for Priority Review Supplemental New Drug Application for Oxbryta® (voxelotor) for the Treatment of Sickle Cell Disease in Children Ages 4 to 11
|
|
|
Sep 02, 2021
|
GBT Announces Participation in Upcoming Investor Conferences
|
|
|
Aug 12, 2021
|
GBT Announces New Employment Inducement Grants
|
|
|
Aug 04, 2021
|
GBT Announces Participation at the Wedbush PacGrow Healthcare Conference
|
|
|
Aug 03, 2021
|
GBT Reports Second Quarter 2021 Financial Results
|
|
|
Jul 27, 2021
|
GBT to Announce Second Quarter 2021 Financial Results on Tuesday, August 3, 2021
|
|
|
Jul 22, 2021
|
GBT Provides Regulatory and Pipeline Updates in Sickle Cell Disease (SCD)
|
|
|
Jul 09, 2021
|
GBT Announces New Employment Inducement Grants
|
|
|
Jun 15, 2021
|
GBT Awards $450,000 in ACCEL Grants to Improve Access to Care in Sickle Cell Disease
|
|
|
Jun 14, 2021
|
GBT’s Voxelotor is First Sickle Cell Disease Treatment to Receive Promising Innovative Medicine (PIM) Designation in the UK
|
|
|
Jun 11, 2021
|
New Data Supporting the Potential Use of Oxbryta® (voxelotor) in Children Ages 4 to 11 Years with Sickle Cell Disease Presented at European Hematology Association 2021 Virtual Congress
|
|
|
Jun 04, 2021
|
GBT Announces New Employment Inducement Grants
|
|
|
Jun 01, 2021
|
GBT Announces Participation at the Goldman Sachs 42nd Annual Global Healthcare Conference
|
|
|
May 12, 2021
|
GBT Announces Upcoming Data Presentations at European Hematology Association (EHA) 2021 Virtual Congress
|
|
|
May 07, 2021
|
GBT Announces New Employment Inducement Grants
|
|
|
May 06, 2021
|
GBT Announces Participation in Upcoming Investor Conferences
|
|
|
May 05, 2021
|
GBT Reports First Quarter 2021 Financial Results
|
|
|
May 04, 2021
|
GBT and Sickle Cell Disease Association of America Kick Off “Lift Every Voice to Shine the Light on Sickle Cell” Spoken Word Contest in Honor of World Sickle Cell Day 2021
|
|
|
Apr 28, 2021
|
GBT to Announce First Quarter 2021 Financial Results on Wednesday, May 5, 2021
|
|
|
Apr 08, 2021
|
Complete 72-Week Results from Phase 3 HOPE Study of Oxbryta® (voxelotor) Tablets Published in The Lancet Haematology Show Significantly Improved Hemoglobin, Hemolysis and Overall Health Status in Sickle Cell Disease Patients
|
|
|
Apr 05, 2021
|
GBT Announces New Employment Inducement Grants
|
|
|
Mar 18, 2021
|
GBT Appoints Alexis A. Thompson, M.D., M.P.H., to Board of Directors
|
|